These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 14696115)

  • 21. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
    Los M; Zeamari S; Foekens JA; Gebbink MF; Voest EE
    Cancer Res; 1999 Sep; 59(17):4440-5. PubMed ID: 10485495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and functional influence of cellular retinoic acid-binding protein II in renal cell carcinoma.
    Goelden U; Pfoertner S; Hansen W; Toepfer T; von Knobloch R; Hofmann R; Buer J; Schrader AJ
    Urol Int; 2005; 75(3):269-76. PubMed ID: 16215318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
    McGarvey TW; Kariko K; Barnathan ES; Thomas J; Malkowicz SB
    Int J Oncol; 1998 Jan; 12(1):175-80. PubMed ID: 9454902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
    Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G
    Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
    Zhang W; Ling D; Tan J; Zhang J; Li L
    Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells.
    Hirashima Y; Kobayashi H; Suzuki M; Tanaka Y; Kanayama N; Terao T
    J Biol Chem; 2003 Jul; 278(29):26793-802. PubMed ID: 12743121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clusterin promotes growth and invasion of clear cell renal carcinoma cell by upregulation of S100A4 expression.
    Liu Y; Men C; Xu Y; Zhao K; Luo L; Dong D; Yu Q
    Cancer Biomark; 2018; 21(4):915-923. PubMed ID: 29400663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
    Matsuyama M; Yoshimura R; Mitsuhashi M; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
    Oncol Rep; 2005 Jul; 14(1):73-9. PubMed ID: 15944770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
    Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-21 downregulated TCF21 to inhibit KISS1 in renal cancer.
    Zhang H; Guo Y; Shang C; Song Y; Wu B
    Urology; 2012 Dec; 80(6):1298-302.e1. PubMed ID: 23206776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.
    España F; Estellés A; Fernández PJ; Gilabert J; Sánchez-Cuenca J; Griffin JH
    Thromb Haemost; 1993 Dec; 70(6):989-94. PubMed ID: 8165623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity.
    Asanuma K; Yoshikawa T; Hayashi T; Akita N; Nakagawa N; Hamada Y; Nishioka J; Kamada H; Gabazza EC; Ido M; Uchida A; Suzuki K
    Int J Cancer; 2007 Sep; 121(5):955-65. PubMed ID: 17450526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.